Vigilant Biosciences names new CEO

Vigilant Biosciences, developer of a "rinse and spit" screening test for the early detection of oral cancer, has appointed David Barshis as its new CEO.

Barshis is an industry veteran with more than 20 years of management experience in diagnostics, biotechnology, and pharmaceuticals, including as chief operating officer of Zila Pharmaceuticals, makers of the ViziLite Plus. He holds a bachelor's degree from the College of William and Mary and a Master of Business Administration from the Kellogg School of Management at Northwestern University.

VigilantBio is a low-cost, selective adjunctive screening test for oral cancer based on technology exclusively licensed from the University of Miami.

Page 1 of 116
Next Page